In this study, we identified PIK-75 as an agent to down-regulate NRF2 protein level and demonstrated its application in combination with gemcitabine to further reduce in vivo tumor growth of human pancreatic cancer. Here, NFE2L2 is linked to pancreatic neoplasm.